Phaseline

Companies › Leadingtac Pharmaceutical (Shaoxing)

Leadingtac Pharmaceutical (Shaoxing): clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 1, 1 Phase 2; Immunology; next expected readout Jan 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
LT-002-158 Tablets–Phase 2Atopic Dermatitis (AD); Hidradenitis Suppurativa (HS)Jan 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07895615LT-002-158 TabletsPhase 2Atopic Dermatitis (AD)ImmunologyJan 2028
NCT06931990LT-002-158 TabletsPhase 1Atopic Dermatitis (AD)ImmunologyFeb 2028
NCT06932003LT-002-158 TabletsPhase 1Hidradenitis Suppurativa (HS)ImmunologyOct 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Calixis Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) Qifeng Zhang Topadur Pharma Agomab Spain S.L.U.

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.